As the use of imatinib grew, case reports on imatinib resistant CML began to appear, indicating that the majority of resistant phenotypes are associated with point mutations in the BCR-ABL kinase domain (Roumiantsev et al., 2002). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.